166 related articles for article (PubMed ID: 37336886)
1. WDR5 facilitates recruitment of N-MYC to conserved WDR5 gene targets in neuroblastoma cell lines.
Bumpous LA; Moe KC; Wang J; Carver LA; Williams AG; Romer AS; Scobee JD; Maxwell JN; Jones CA; Chung DH; Tansey WP; Liu Q; Weissmiller AM
Oncogenesis; 2023 Jun; 12(1):32. PubMed ID: 37336886
[TBL] [Abstract][Full Text] [Related]
2. Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance.
Thomas LR; Adams CM; Wang J; Weissmiller AM; Creighton J; Lorey SL; Liu Q; Fesik SW; Eischen CM; Tansey WP
Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25260-25268. PubMed ID: 31767764
[TBL] [Abstract][Full Text] [Related]
3. Mitotic gene regulation by the N-MYC-WDR5-PDPK1 nexus.
Streeter SA; Williams AG; Evans JR; Wang J; Guarnaccia AD; Florian AC; Al-Tobasei R; Liu Q; Tansey WP; Weissmiller AM
BMC Genomics; 2024 Apr; 25(1):360. PubMed ID: 38605297
[TBL] [Abstract][Full Text] [Related]
4. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.
Sun Y; Bell JL; Carter D; Gherardi S; Poulos RC; Milazzo G; Wong JW; Al-Awar R; Tee AE; Liu PY; Liu B; Atmadibrata B; Wong M; Trahair T; Zhao Q; Shohet JM; Haupt Y; Schulte JH; Brown PJ; Arrowsmith CH; Vedadi M; MacKenzie KL; Hüttelmaier S; Perini G; Marshall GM; Braithwaite A; Liu T
Cancer Res; 2015 Dec; 75(23):5143-54. PubMed ID: 26471359
[TBL] [Abstract][Full Text] [Related]
5. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC.
Thomas LR; Wang Q; Grieb BC; Phan J; Foshage AM; Sun Q; Olejniczak ET; Clark T; Dey S; Lorey S; Alicie B; Howard GC; Cawthon B; Ess KC; Eischen CM; Zhao Z; Fesik SW; Tansey WP
Mol Cell; 2015 May; 58(3):440-52. PubMed ID: 25818646
[TBL] [Abstract][Full Text] [Related]
6. Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders.
Gurung R; Om D; Pun R; Hyun S; Shin D
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568727
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.
Ding J; Liu L; Chiang YL; Zhao M; Liu H; Yang F; Shen L; Lin Y; Deng H; Gao J; Sage DR; West L; Llamas LA; Hao X; Kawatkar S; Li E; Jain RK; Tallarico JA; Canham SM; Wang H
J Med Chem; 2023 Jun; 66(12):8310-8323. PubMed ID: 37307526
[TBL] [Abstract][Full Text] [Related]
8. WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways.
Chen T; Li K; Liu Z; Liu J; Wang Y; Sun R; Li Z; Qiu B; Zhang X; Ren G; Xu Y; Zhang Z
Mol Ther; 2021 Jun; 29(6):2134-2150. PubMed ID: 33601056
[TBL] [Abstract][Full Text] [Related]
9. WDR5 is a conserved regulator of protein synthesis gene expression.
Bryan AF; Wang J; Howard GC; Guarnaccia AD; Woodley CM; Aho ER; Rellinger EJ; Matlock BK; Flaherty DK; Lorey SL; Chung DH; Fesik SW; Liu Q; Weissmiller AM; Tansey WP
Nucleic Acids Res; 2020 Apr; 48(6):2924-2941. PubMed ID: 31996893
[TBL] [Abstract][Full Text] [Related]
10. WDR5-Myc axis promotes the progression of glioblastoma and neuroblastoma by transcriptional activating CARM1.
Wang F; Zhang J; Ke X; Peng W; Zhao G; Peng S; Xu J; Xu B; Cui H
Biochem Biophys Res Commun; 2020 Mar; 523(3):699-706. PubMed ID: 31948749
[TBL] [Abstract][Full Text] [Related]
11. The MYC-WDR5 Nexus and Cancer.
Thomas LR; Foshage AM; Weissmiller AM; Tansey WP
Cancer Res; 2015 Oct; 75(19):4012-5. PubMed ID: 26383167
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.
Tian J; Teuscher KB; Aho ER; Alvarado JR; Mills JJ; Meyers KM; Gogliotti RD; Han C; Macdonald JD; Sai J; Shaw JG; Sensintaffar JL; Zhao B; Rietz TA; Thomas LR; Payne WG; Moore WJ; Stott GM; Kondo J; Inoue M; Coffey RJ; Tansey WP; Stauffer SR; Lee T; Fesik SW
J Med Chem; 2020 Jan; 63(2):656-675. PubMed ID: 31858797
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction.
Ding J; Li G; Liu H; Liu L; Lin Y; Gao J; Zhou G; Shen L; Zhao M; Yu Y; Guo W; Hommel U; Ottl J; Blank J; Aubin N; Wei Y; He H; Sage DR; Atadja PW; Li E; Jain RK; Tallarico JA; Canham SM; Chiang YL; Wang H
ACS Chem Biol; 2023 Jan; 18(1):34-40. PubMed ID: 36594833
[TBL] [Abstract][Full Text] [Related]
14. Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design.
Chacón Simon S; Wang F; Thomas LR; Phan J; Zhao B; Olejniczak ET; Macdonald JD; Shaw JG; Schlund C; Payne W; Creighton J; Stauffer SR; Waterson AG; Tansey WP; Fesik SW
J Med Chem; 2020 Apr; 63(8):4315-4333. PubMed ID: 32223236
[TBL] [Abstract][Full Text] [Related]
15. Overlapping characteristics of weak interactions of two transcriptional regulators with WDR5.
Ahmad M; Imran A; Movileanu L
Int J Biol Macromol; 2024 Feb; 258(Pt 2):128969. PubMed ID: 38158065
[TBL] [Abstract][Full Text] [Related]
16. MYCN driven oncogenesis involves cooperation with WDR5 to activate canonical MYC targets and G9a to repress differentiation genes.
Liu Z; Zhang X; Xu M; Hong JJ; Ciardiello A; Lei H; Shern JF; Thiele CJ
bioRxiv; 2023 Jul; ():. PubMed ID: 37781575
[TBL] [Abstract][Full Text] [Related]
17. The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer.
Lu K; Tao H; Si X; Chen Q
Front Oncol; 2018; 8():502. PubMed ID: 30488017
[TBL] [Abstract][Full Text] [Related]
18. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
[No Abstract] [Full Text] [Related]
19. WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage.
Neilsen BK; Chakraborty B; McCall JL; Frodyma DE; Sleightholm RL; Fisher KW; Lewis RE
BMC Cancer; 2018 Jun; 18(1):673. PubMed ID: 29925347
[TBL] [Abstract][Full Text] [Related]
20. A clustering of heterozygous missense variants in the crucial chromatin modifier WDR5 defines a new neurodevelopmental disorder.
Snijders Blok L; Verseput J; Rots D; Venselaar H; Innes AM; Stumpel C; Õunap K; Reinson K; Seaby EG; McKee S; Burton B; Kim K; van Hagen JM; Waisfisz Q; Joset P; Steindl K; Rauch A; Li D; Zackai EH; Sheppard SE; Keena B; Hakonarson H; Roos A; Kohlschmidt N; Cereda A; Iascone M; Rebessi E; Kernohan KD; Campeau PM; Millan F; Taylor JA; Lochmüller H; Higgs MR; Goula A; Bernhard B; Velasco DJ; Schmanski AA; Stark Z; Gallacher L; Pais L; Marcogliese PC; Yamamoto S; Raun N; Jakub TE; Kramer JM; den Hoed J; Fisher SE; Brunner HG; Kleefstra T
HGG Adv; 2023 Jan; 4(1):100157. PubMed ID: 36408368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
